GlassScriptPhysician profile
Keith Bass
NPI 1114440179
$31,054.47
in general payments reported to CMS, 2019-2025
11 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $465 · 2022: $527 · 2023: $472 · 2024: $19K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $2,749 · Travel and Lodging: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,737.50 |
| Food and Beverage | $2,749.28 |
| Travel and Lodging | $1,574.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,635.51 | 2021-2025 | |
| Alkermes, INC. | $410.53 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $304.83 | 2023-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $279.35 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $155.68 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $77.52 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $58.46 | 2021-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $52.64 | 2021 | |
| Supernus Pharmaceuticals, INC. | $33.25 | 2023-2024 | Qelbree, Qelbree |
| Uswm, LLC | $30.86 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $15.84 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Bass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.